Opinion & analysis

Orphan Drug Pricing And Reimbursement: Challenges To Patient Access

While the drug industry and patient advocacy groups have worried about price controls or reimbursement restrictions for drugs that treat orphan diseases, a review of formulary data shows that patient access to high-priced drugs has not been severely hampered despite some payer pushback.

Orphan Drug Pricing And Reimbursement: Challenges To Patient Access

Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition

Sanofi’s New CEO Paul Hudson Poised To Write The Next Chapter

Peter Stein Takes Short Path To Director Of US FDA Drug Office

Transforming Pharmaceutical R&D with Data

Innovations In Market Access: The Will, But Not The Way?

CBD Suits Challenge ‘THC-Free’ Claims After Users Fail Drug Tests; Plaintiffs Bar May Just Be Warming Up

EMA Set For More Staff Losses & Activity Cuts Next Year

GSK And Pfizer Start Consumer JV For Different Reasons, Aim For Similar Goals

Brexit At The 11th Hour: UK Refreshes No-Deal Guidance For Medtech

Gene Therapy’s Next Big Challenge: Manufacturing

Analysts Weigh Up Benefits Of Big Bayer Restructuring

Telehealth Reforms Praised At Senate Hearing

Interventional Neurology: Cerebral Aneurysm and Arteriovenous Malformation Systems

Real-World Evidence: US FDA’s Prucalopride Review Shows Datasets’ Utility And Limitations